Web Exclusives

Post-hoc analysis of the CheckMate-032 study found PD-L1 expression by combined positive score was more closely associated with nivolumab and ipilimumab therapy efficacy compared with percentage of positive tumor cells PD-L1 expression in advanced gastric/gastroesophageal junction cancer. Read More ›

Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy. Read More ›

Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy. Read More ›

Nivolumab with paclitaxel plus ramucirumab as second-line therapy in patients with advanced gastric cancer demonstrated promising responses with manageable treatment-related adverse events. Read More ›

In patients receiving treatment with CDK4/6 inhibitors, levels of neutralizing antibodies post-vaccination were similar to those in matched healthy controls. Read More ›

Although CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative advanced breast cancer improve progression-free survival, this therapeutic intervention is also associated with higher rates of adverse events. Read More ›

To ensure the correct use of healthcare services, it is critical to invest in training nursing professionals who must educate patients on the timely recognition and management of complications. Read More ›


Research suggests that, when used in routine clinical practice in first or subsequent lines of treatment, ribociclib and palbociclib resulted in toxicity and efficacy outcomes in agreement with pivotal trial expectations. Read More ›

A recently released MYLUNG study found that most patients with untreated metastatic NSCLC tested for ≥1 biomarkers, but <50% of patients had ≥5 biomarker tests. Read More ›

Page 5 of 47


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: